AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19Jul 20, 2026
BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01Jun 2, 2026
Continuous VV
The Stepwise Future of Continuous Viral Vector Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-12Jun 1, 2026
Psychedelics CMC
The CMC Challenge for Psychedelic Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-21May 22, 2026
Conjugation
Why ADC Conjugation Strategy Is Now a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-18May 20, 2026
ADC Linkers
Linker Chemistry as the Hidden Determinant of ADC Success
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-10May 8, 2026
Sustainable CIP
Sustainable Clean-in-Place: Rethinking Legacy Chemistry in Modern Biomanufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-CL-02May 7, 2026
cell therapy
State of the Cell and Gene Therapy Market
James Grote
Nice Insight
PAO-10-022-NI-01Oct 11, 2022